Evidence map›Paper›PMID 27794120›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2016

BMP-SMAD-ID promotes reprogramming to pluripotency by inhibiting p16/INK4A-dependent senescence.

Yohei Hayashi, Edward C Hsiao, Salma Sami, Mariselle Lancero, Christopher R Schlieve, Trieu Nguyen, Koyori Yano, Ayako Nagahashi, Makoto Ikeya, Yoshihisa Matsumoto and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 115 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Reprogramming of Human Limbal Niche Progenitors.International journal of medical sciences · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Yohei HayashiGladstone Institute of Cardiovascular Disease, San Francisco, CA 94158; yamanaka@cira.kyoto-u.ac.jp yohei.hayashi@md.tsukuba.ac.jp.
Edward C HsiaoDepartment of Medicine and the Institute for Human Genetics, University of California, San Francisco, CA 94143.
Salma SamiGladstone Institute of Cardiovascular Disease, San Francisco, CA 94158.
Mariselle LanceroGladstone Institute of Cardiovascular Disease, San Francisco, CA 94158.
Christopher R SchlieveGladstone Institute of Cardiovascular Disease, San Francisco, CA 94158.
Trieu NguyenGladstone Institute of Cardiovascular Disease, San Francisco, CA 94158.
Koyori YanoDepartment of Fundamental Cell Technology, Center for iPS Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan.
Ayako NagahashiDepartment of Fundamental Cell Technology, Center for iPS Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan.
Makoto IkeyaDepartment of Life Sciences Frontiers, Center for iPS Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan.
Yoshihisa MatsumotoDepartment of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan.
Ken NishimuraLaboratory of Gene Regulation, Faculty of Medicine, University of Tsukuba, Ibaraki 305-8575, Japan.
Aya FukudaLaboratory of Gene Regulation, Faculty of Medicine, University of Tsukuba, Ibaraki 305-8575, Japan.
Koji HisatakeLaboratory of Gene Regulation, Faculty of Medicine, University of Tsukuba, Ibaraki 305-8575, Japan.
Kiichiro TomodaGladstone Institute of Cardiovascular Disease, San Francisco, CA 94158.
Isao AsakaDepartment of Fundamental Cell Technology, Center for iPS Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan.
Junya ToguchidaDepartment of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan.
Bruce R ConklinGladstone Institute of Cardiovascular Disease, San Francisco, CA 94158.
Shinya YamanakaGladstone Institute of Cardiovascular Disease, San Francisco, CA 94158; yamanaka@cira.kyoto-u.ac.jp yohei.hayashi@md.tsukuba.ac.jp.
Kyoto University · JPGladstone Institutes · USUniversity of Tsukuba · JPUniversity of California, San Francisco · US

Funding

Tissue Engineering with a Modular RASSL ToolboxR01HL060664 · NHLBI · J. DAVID GLADSTONE INSTITUTES · PI CONKLIN, BRUCE R · 1998 to 2012
$7.0M
EXTRAMULAR RESEARCH FACILITIES CONSTRUCTIONC06RR018928 · NCRR · J. DAVID GLADSTONE INSTITUTES · PI MAHLEY, ROBERT W. · 2003 to 2003
$2.1M
Regulation of Bone Formation by G-protein SignalingK08AR056299 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSIAO, EDWARD C · 2009 to 2013
$640k
NCRR NIH HHS C06 RR018928NHLBI NIH HHS R01 HL060664NIAMS NIH HHS K08 AR056299
6 · The paper itself

Abstract

Fibrodysplasia ossificans progressiva (FOP) patients carry a missense mutation in ACVR1 [617G > A (R206H)] that leads to hyperactivation of BMP-SMAD signaling. Contrary to a previous study, here we show that FOP fibroblasts showed an increased efficiency of induced pluripotent stem cell (iPSC) generation. This positive effect was attenuated by inhibitors of BMP-SMAD signaling (Dorsomorphin or LDN1931890) or transducing inhibitory SMADs (SMAD6 or SMAD7). In normal fibroblasts, the efficiency of iPSC generation was enhanced by transducing mutant ACVR1 (617G > A) or SMAD1 or adding BMP4 protein at early times during the reprogramming. In contrast, adding BMP4 at later times decreased iPSC generation. ID genes, transcriptional targets of BMP-SMAD signaling, were critical for iPSC generation. The BMP-SMAD-ID signaling axis suppressed p16/INK4A-mediated cell senescence, a major barrier to reprogramming. These results using patient cells carrying the ACVR1 R206H mutation reveal how cellular signaling and gene expression change during the reprogramming processes.

Indexed as

Myositis OssificansActivin Receptors, Type IAdolescentAdultAnimalsBone Morphogenetic ProteinsCell LineCellular ReprogrammingCellular SenescenceChildCyclin-Dependent Kinase Inhibitor p16FemaleFibroblastsHumansInduced Pluripotent Stem CellsMaleActivin Receptors, Type IACVR1 protein, humanBone Morphogenetic ProteinsCyclin-Dependent Kinase Inhibitor p16Smad ProteinsBMPFOPpluripotencyreprogrammingsenescence

Identifiers

PMID27794120
PMCPMC5135304
OpenAlexW2546362712

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.